Deals: Page 19
-
Neurocrine stocks up on a biotech's psychiatric drugs
A new deal with Sosei Heptares hands Neurocrine a "broad portfolio" of drugs for schizophrenia, dementia and other neuropsychiatric disorders.
By Jacob Bell • Nov. 22, 2021 -
Permission granted by Gilead Sciences
Gilead pays up to retain rights to Arcus cancer drugs
The biotech will pay $725 million to opt into rights on four experimental medicines developed by Arcus, including ones that could challenge Merck's Keytruda in lung cancer.
By Jonathan Gardner • Nov. 18, 2021 -
Novo to acquire Dicerna for more than $3B amid RNA drug resurgence
The acquisition would give Novo Nordisk ownership of one of the oldest and largest developers of RNA interference drugs, along with a web of potential royalty streams.
By Ben Fidler • Updated Nov. 18, 2021 -
Permission granted by Biohaven Pharmaceuticals
Pfizer buys into Biohaven's fast-selling migraine medicine
The pharmaceutical giant will pay Biohaven $500 million for ex-U.S. rights to rimegepant — a sizable licensing deal, though not the buyout that some of the biotech's investors appeared to be hoping for.
By Ned Pagliarulo • Nov. 9, 2021 -
Courtesy of Sanofi
Eye-focused gene therapy startup gets $60M cash infusion from Sanofi
Shortly after postponing a $135 million IPO, Gyroscope has found another way to back a treatment for a disease that's become a top target of multiple drugmakers.
By Jonathan Gardner • Nov. 8, 2021 -
Novartis to sell long-held stake in Roche for nearly $21B
Novartis, which paid around $5 billion for its shares two decades ago, says it will gain about $14 billion from its sale and use the proceeds to further its current strategy.
By Jacob Bell • Nov. 4, 2021 -
Getty / Edited by BioPharma Dive
Cystic fibrosis group partners with Moderna founder to find better, potentially curative treatments
With an initial investment of $20 million, the collaboration will use technologies from various Flagship-backed companies to discover and develop new therapies for the disease.
By Jacob Bell • Nov. 3, 2021 -
Courtesy of Intellia Therapeutics
Intellia looks to eye diseases in latest deal
The gene editing company will take a 10% stake in SparingVision, a young biotech that will use Intellia's CRISPR technology to develop treatments for up to three ocular targets.
By Jacob Bell • Oct. 13, 2021 -
Takeda takes aim at a biotech's gene therapy work
For an upfront payment of $45 million, Takeda gains access to as many as eight programs from Poseida Therapeutics and a potential method of delivering gene therapies without the help of viruses.
By Jacob Bell • Oct. 12, 2021 -
Elizabeth Regan/BioPharma Dive
Adamas, Flexion sell for $825M combined as biotech's dealmaking pace picks up
After lagging for months, M&A has accelerated over the past five weeks. The latest evidence comes from two deals based largely on future drug sales.
By Jonathan Gardner • Oct. 11, 2021 -
Otsuka partners with Sunovion, Sumitomo in neurology drug pact
Sunovion will receive $270 million from Otsuka, and as much as $620 million more, in exchange for splitting rights to four experimental psychiatric drugs.
By Kristin Jensen • Sept. 30, 2021 -
Acceleron provides biggest biopharma deal this year, with $11.5B sale to Merck
The acquisition is notable for Merck, which is under pressure to diversify its business beyond the cancer drug Keytruda and has typically favored smaller buyouts of earlier-stage companies.
By Jacob Bell • Updated Sept. 30, 2021 -
Getty / Edited by BioPharma Dive
Amicus, looking for a boost, sells its gene therapy work to a SPAC
The value of the biotech's growing gene therapy portfolio has been "unrecognized" by investors, said CEO John Crowley, leading to a sudden shift for an initiative that began just three years ago.
By Ben Fidler • Sept. 29, 2021 -
Christopher Furlong via Getty Images
AstraZeneca to buy rare disease drugmaker Caelum in small deal
The British pharma inherited an option to acquire Caelum Biosciences when it bought Alexion last year. Caelum could receive as much as $500 million as a result of the planned buyout.
By Kristin Jensen • Sept. 29, 2021 -
AbbVie bets big on a gene therapy for eye diseases
The company has agreed to pay $370 million, and possibly north of $1 billion more, to gain access to a Regenxbio treatment targeting wet AMD and other eye conditions.
By Jacob Bell • Sept. 13, 2021 -
Courtesy of Sanofi
Sanofi to buy Kadmon for $1.9B, extending deal streak
The acquisition took some analysts by surprise as Sanofi has recently targeted specialty drugs, not general medicines like Kadmon's transplant treatment.
By Ben Fidler • Sept. 8, 2021 -
Roche bets big on off-the-shelf cancer cell therapy with Adaptimmune deal
Long a bystander in the race to develop so-called allogeneic treatments, the cancer drugmaking giant has joined the fray with a wide-ranging alliance that could be worth up to $3 billion.
By Jonathan Gardner • Sept. 7, 2021 -
Courtesy of Eli Lilly
Lilly puts more money into protein degradation
The pharma has struck its second research pact focused on drugs that break down harmful proteins in as many years, this time with California biotech Lycia Therapeutics.
By Jacob Bell • Aug. 25, 2021 -
Jeenah Moon via Getty Images
Pfizer stocks cancer drug pipeline with $2.3B deal for Trillium
The acquisition reflects growing industry interest in the cancer-linked protein targeted by Trillium's drugs, most notably shown by Gilead's acquisition of Forty Seven last year.
By Ned Pagliarulo • Aug. 23, 2021 -
Illumina closes Grail takeover despite pending FTC trial
The testing giant's decision to move ahead without sign-off from U.S. regulators and an EU investigation ongoing is a "maverick move," said Evercore analysts, as there's a chance Illumina may have to unwind the takeover.
By Nick Paul Taylor • Aug. 19, 2021 -
Adeline Kon/BioPharma Dive
Deep DiveBiotech’s M&A outlook is uncertain. Track the deals that are happening here.
Novartis' acquisition of Avidity Biosciences is the year’s second-largest by total consideration, trailing only Johnson & Johnson’s $14.6 billion buyout of Intra-Cellular Therapies in January.
By Ned Pagliarulo, Jacob Bell, Julia Himmel • Updated Oct. 24, 2025 -
How Bayer lured a biotech away from an IPO and into a buyout
Vividion Therapeutics was headed toward an IPO earlier this year, but the company's co-founder said Bayer’s $1.5 billion offer ended up being a more attractive option.
By Shoshana Dubnow • Aug. 5, 2021 -
Courtesy of Sanofi
Sanofi bets $3.2B on mRNA with deal to buy Translate Bio
The acquisition is a sign of how more and more large pharmaceutical companies view messenger RNA as an essential drugmaking technology.
By Ned Pagliarulo • Aug. 3, 2021 -
Bluebird preps for split by selling manufacturing plant to well-funded startup
The startup manufacturing specialist National Resilience, which raised $800 million when it launched last year, will pay Bluebird $110 million for the North Carolina facility, bringing its North American network up to 10.
By Kristin Jensen • July 29, 2021 -
Amgen pays $900M for Teneobio and bets bigger on next-gen antibody drugs
The acquisition is the third Amgen has made since March and broadens its ability to develop bispecific antibodies, a drug class of intense interest to big biotech.
By Ben Fidler • July 28, 2021
Previous
